A Study on Radiation-induced Pulmonary Fibrosis Treated With Clinical Grade Umbilical Cord Mesenchymal Stem Cells

Phase 1

Completed

• Conditions: Post-radiotherapy Pulmonary Fibrosis
• Interventions: Biological: clinical grade umbilical cord mesenchymal stem cells

• Registration Number: NCT02277145
• Lead Sponsor: Jianwu Dai

Brief Summary

Radiation therapy is one of the main means for treating malignant tumor, during which radioactive lung injury is inevitable. Currently there is nearly no effective clinical treatment for late post-radiotherapy pulmonary fibrosis. This study intends to carry out an open, single-center, non-randomized phase I clinical trial. During the treatment, the local lesions will be fully lavaged, and then clinical grade umbilical cord mesenchymal stem cells (MSCs) will be injected directly into the lesion by fiberoptic bronchoscopy. After six-month observation, the investigators will initially evaluate the safety and effectiveness of the treatment by measuring two key indicators-the CT density histogram and the patients' self-evaluation, and one secondary indicator-the changes of TGF-β1 contents, both before and after the treatment. Meanwhile, the investigators will make a preliminary discuss about the possible immunomodulatory effects of the umbilical cord MSCs.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-10
• Study First Submitted: 2014-10-20
• Study First Submitted QC: 2014-10-26
• Study First Posted: 2014-10-28
• Status Verified: 2018-07
• Primary Completion: 2018-12
• Study Completion: 2018-12
• Last Update Submitted: 2019-07-23
• Last Update Posted: 2019-07-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

1. Male or female, 18-70 years old.
2. Subjects with a clear history of malignancy.
3. Subjects with a clear history of chest radiation therapy at least 3 months earlier.
4. Subjects diagnosed as chronic phase of radiation-induced pneumonitis or radiation-induced pulmonary fibrosis stage (see Annex 3 for diagnosis).
5. Subjects signed informed consent.

Exclusion Criteria

1. Women of childbearing age at the stage of pregnancy or lactation, or those without taking effective contraceptive measures.
2. Subjects with syphilis or HIV positive antibody.
3. Subjects with infection aggravated within the past month.
4. Subjects suffering from any of the following pulmonary diseases: active tuberculosis, pulmonary embolism, pneumothorax, multiple huge bullae, uncontrolled asthma, severe pneumonia, acute exacerbation of chronic bronchitis, AECOPD, severe and / or extremely severe COPD, etc..
5. Subjects suffering from other serious diseases, such as myocardial infarction, unstable angina, cirrhosis, and acute glomerulonephritis.
6. Subjects with progression-free survival (PFS) less than 0.5 years or Karnofsky performance scores less than 60 points.
7. Subjects with leukopenia (WBC less than 4x109 / L) or agranulocytosis (WBC less than 1.5x109 / L or neutrophils less than 0.5x109 / L) caused by any reason.
8. Subjects with severe renal impairment, serum creatinine> 1.5 times the upper limit of normal.
9. Subjects with liver disease or liver damage: ALT, AST, total bilirubin> 2 times the upper limit of normal
10. Subjects with a history of mental illness or suicide risk, with a history of epilepsy or other central nervous system disorders.
11. Subjects with severe arrhythmias (such as ventricular tachycardia, frequent superventricular tachycardia, atrial fibrillation, and atrial flutter, etc.) or cardiac degree II or above conduction abnormalities displayed via 12-lead ECG.
12. Subjects with a history of alcohol or illicit drug abuse.
13. Subjects accepted by any other clinical trials within 3 months before the enrollment
14. Subjects with poor compliance, difficult to complete the study.
15. Any other conditions that might increase the risk of subjects or interfere with the clinical trial.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
treatment group	clinical grade umbilical cord mesenchymal stem cells	Patients will receive 10\^6 (1 million) /Kg/person cells of clinical grade umbilical cord mesenchymal stem cells (MSCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions

Primary Outcome Measures

Name	Time	Method
Composite indicators, including quantitative analysis of CT density histograms, self-evaluation and changes of TGF-β1 content	6 months	Different proportions will be assigned to the three indicators. The overall curative effect can be judged with scores ranging from 0 to100. Specific proportions are as follows: full scores of 50 points for image changes, 25 for self-efficacy evaluation and 25 for TGF-β1 content changes. The image changes can be classified into four levels: significant control, improved, stable, and progressive; the self-efficacy evaluation can also be classified into four levels: effective, improved, stable and invalid; the changes of TGF-β1 content will be classified into three levels: improved, stable, and progressive. The four levels will be scored on the ratio of 5:4:3:1, the three levels will be scored on the ratio of 5:3:1.
Safety Evaluation	6 months	Clinical adverse events evaluated as definitely/ probably/possibly concerned with stem cell therapy in this trial and abnormal results of laboratory tests or other special examinations will be observed and recorded in detail.

Secondary Outcome Measures

Name	Time	Method
Clinical Indicator 2: change in pulmonary function analysis	3-6 months
Fibrosis Indicators in lavage fluid 3: content of matrix metalloproteinase 1/7(MMP1/MMP7)	6 months	Content of matrix metalloproteinase 1/7(MMP1/MMP7) measured in lavage fluid
Clinical Indicator 3: 6-minute walk test distance	3-6 months
Immunological Indicator in serum 2: response level of CD4+ T lymphocyte subsets (such as Th1 / Th2)	3-6 months	Cellular immunological indicator: response level of CD4+ T lymphocyte subsets (such as Th1 / Th2) measured in serum
Immunological Indicator in lavage fluid 5: subtype analysis and phagocytic activity analysis of macrophage	6 months	Macrophage-related polarization indicator: subtype analysis and phagocytic activity of macrophage measured in lavage fluid
Fibrosis Indicators in serum 3: content of matrix metalloproteinase 1/7(MMP1/MMP7)	3-6 months	Content of matrix metalloproteinase 1/7(MMP1/MMP7) measured in serum
Clinical Indicator 4: change in MRC chronic dyspnea scale	3-6 months
Clinical Indicator 5: change in St. George's Respiratory Questionnaire (SGRQ) scale	3-6 months
Immunological Indicator in serum 6: expression levels of IL-12, IL-10	3-6 months	Macrophage- related polarization indicators: expression levels of IL-12, IL-10 measured in serum
Clinical Indicator 1: change in blood gas analysis	3-6 months
Immunological Indicator in serum 3: concent of immunoglobulin	3-6 months	Humoral immunological indicator: concent of immunoglobulin measured in serum
Immunological Indicator in serum 5: subtype analysis and phagocytic activity analysis of macrophage	3-6 months	Macrophage-related polarization indicator: subtype analysis and phagocytic activity of macrophage measured in serum
Immunological Indicator in lavage fluid 2: response level of CD4+ T lymphocyte subsets (such as Th1 / Th2)	6 months	Cellular immunological indicator: response level of CD4+ T lymphocyte subsets (such as Th1 / Th2) measured in lavage fluid
Immunological Indicator in lavage fluid 4: expression levels of various cytokines (IL-1, IL-3, IL-6, IL-8, TNF-α, GM-CSF, etc)	6 months	Humoral immunological indicator: expression levels of various cytokines (IL-1, IL-3, IL-6, IL-8, TNF-α, GM-CSF, etc) measured in lavage fluid
Inflammatory Indicators: measured by routine blood test including C-reactive protein (CRP)	3 months
Fibrosis Indicators in serum 2: content of hydroxyproline	3-6 months	Content of hydroxyproline measured in serum
Immunological Indicator in serum 4: expression levels of various cytokines (IL-1, IL-3, IL-6, IL-8, TNF-α, GM-CSF, etc)	3-6 months	Humoral immunological indicator: expression levels of various cytokines in serum (IL-1, IL-3, IL-6, IL-8, TNF-α, GM-CSF, etc) measured in serum
Immunological Indicator in lavage fluid 1: T lymphocyte counts in peripheral blood	6 months	Cellular immunological indicator: T lymphocyte counts in peripheral blood measured in lavage fluid
Immunological Indicator in lavage fluid 6: expression levels of IL-12, IL-10	6 months	Macrophage-related polarization indicators: expression levels of IL-12, IL-10 measured in lavage fluid
Fibrosis Indicators in serum 1: content of transforming growth factor -α/β (TGF-α/TGF-β)	3-6 months	Content of transforming growth factor α/β (TGF-α/TGF-β) measured in serum
Immunological Indicator in serum 1: T lymphocyte counts in peripheral blood	3-6 months	Cellular immunological indicator: T lymphocyte counts in peripheral blood measured in serum
Immunological Indicator in lavage fluid 3: concent of immunoglobulin	6 months	Humoral immunological indicator: concent of immunoglobulin measured in lavage fluid
Fibrosis Indicators in lavage fluid 1: content of transforming growth factor -α/β (TGF-α/TGF-β)	6 months	Content of transforming growth factor -α/β (TGF-α/TGF-β) measured in lavage fluid
Fibrosis Indicators in lavage fluid 2: content of hydroxyproline	6 months	Content of hydroxyproline measured in lavage fluid measured in lavage fluid

Trial Locations

Locations (1)

First Affiliated Hospital of the Third Military University, PLA (Southwest Hospital); 🇨🇳 Chongqing, Chongqing, China